Search Results - "Spring, Laura M."

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer by Brett, Jamie O, Spring, Laura M, Bardia, Aditya, Wander, Seth A

“…In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen…”
Get full text

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis by Spring, Laura M, Fell, Geoffrey, Arfe, Andrea, Sharma, Chandni, Greenup, Rachel, Reynolds, Kerry L, Smith, Barbara L, Alexander, Brian, Moy, Beverly, Isakoff, Steven J, Parmigiani, Giovanni, Trippa, Lorenzo, Bardia, Aditya

“…While various studies have highlighted the prognostic significance of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of…”
Get full text

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations by Spring, Laura M., Zangardi, Mark L., Moy, Beverly, Bardia, Aditya

“…Aberrations of the cell cycle are pervasive in cancer, and selective cell cycle inhibition of cancer cells is a target of choice for a number of novel cancer…”
Get full text

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions by Spring, Laura M., Wander, Seth A., Zangardi, Mark, Bardia, Aditya

“…Purpose of Review To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current…”
Get full text

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models by Keklikoglou, Ioanna, Cianciaruso, Chiara, Güç, Esra, Squadrito, Mario Leonardo, Spring, Laura M., Tazzyman, Simon, Lambein, Lore, Poissonnier, Amanda, Ferraro, Gino B., Baer, Caroline, Cassará, Antonino, Guichard, Alan, Iruela-Arispe, M. Luisa, Lewis, Claire E., Coussens, Lisa M., Bardia, Aditya, Jain, Rakesh K., Pollard, Jeffrey W., De Palma, Michele

“…Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has…”
Get full text

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer by Kwan, Tanya T, Bardia, Aditya, Spring, Laura M, Giobbie-Hurder, Anita, Kalinich, Mark, Dubash, Taronish, Sundaresan, Tilak, Hong, Xin, LiCausi, Joseph A, Ho, Uyen, Silva, Erin J, Wittner, Ben S, Sequist, Lecia V, Kapur, Ravi, Miyamoto, David T, Toner, Mehmet, Haber, Daniel A, Maheswaran, Shyamala

“…The multiplicity of new therapies for breast cancer presents a challenge for treatment selection. We describe a 17-gene digital signature of breast circulating…”
Get more information

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial by Goel, Shom, Pernas, Sonia, Tan-Wasielewski, Zhenying, Barry, William T., Bardia, Aditya, Rees, Rebecca, Andrews, Chelsea, Tahara, Rie Kawabori, Trippa, Lorenzo, Mayer, Erica L., Winer, Eric P., Spring, Laura M., Tolaney, Sara M.

“…Signaling through the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway can mediate therapeutic resistance in HER2-positive breast cancer. Preclinical studies…”
Get full text

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer by McLaughlin, Shannon, Nakajima, Erika, Bar, Yael, Hutchinson, Jennifer A., Shin, Jennifer, Moy, Beverly, Isakoff, Steven J., Bardia, Aditya, Kuter, Irene, Spring, Laura M.

“…Background: The single-arm phase II APT trial established trastuzumab and paclitaxel (TH) as the standard adjuvant regimen for small human epidermal growth…”
Get full text

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer by Waks, Adrienne G., Desai, Neelam V., Li, Tianyu, Poorvu, Philip D., Partridge, Ann H., Sinclair, Natalie, Spring, Laura M., Faggen, Meredith, Constantine, Michael, Metzger, Otto, Alberti, Jillian, Deane, Julia, Rosenberg, Shoshana M., Frank, Elizabeth, Tolaney, Sara M., Krop, Ian E., Tung, Nadine M., Tayob, Nabihah, King, Tari A., Mittendorf, Elizabeth A., Winer, Eric P.

“…De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor…”
Get full text

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future by Spring, Laura M, Wander, Seth A, Andre, Fabrice, Moy, Beverly, Turner, Nicholas C, Bardia, Aditya

“…The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for hormone receptor-positive and human epidermal growth factor receptor 2…”
Get full text

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer by Spring, Laura M., Clark, Shealagh L., Li, Tianyu, Goel, Shom, Tayob, Nabihah, Viscosi, Elene, Abraham, Elizabeth, Juric, Dejan, Isakoff, Steven J., Mayer, Erica, Moy, Beverly, Supko, Jeffrey G., Tolaney, Sara M., Bardia, Aditya

“…Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong…”
Get full text

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer by Denault, Elyssa, Nakajima, Erika, Naranbhai, Vivek, Hutchinson, Jennifer A., Mortensen, Lindsey, Neihoff, Elizabeth, Barabell, Caroline, Comander, Amy, Juric, Dejan, Kuter, Irene, Mulvey, Theresa, Peppercorn, Jeffrey, Rosenstock, Aron S., Shin, Jennifer, Vidula, Neelima, Wander, Seth A., Moy, Beverly, Ellisen, Leif W., Isakoff, Steven J., Iafrate, A. John, Gainor, Justin F., Bardia, Aditya, Spring, Laura M.

“…Purpose: To explore the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with breast cancer based on type of…”
Get full text

Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities by Lloyd, Maxwell R, Spring, Laura M, Bardia, Aditya, Wander, Seth A

“…The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become the standard of care, in combination with antiestrogen therapy, for patients with hormone…”
Get full text

Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses by Koh, Siang-Boon, Dontchos, Brian N., Bossuyt, Veerle, Edmonds, Christine, Cristea, Simona, Melkonjan, Nsan, Mortensen, Lindsey, Ma, Annie, Beyerlin, Kassidy, Denault, Elyssa, Niehoff, Elizabeth, Hirz, Taghreed, Sykes, David B., Michor, Franziska, Specht, Michelle, Lehman, Constance, Ellisen, Leif W., Spring, Laura M.

“…Systematic collection of fresh tissues for research at the time of diagnostic image-guided breast biopsy has the potential to fuel a wide variety of innovative…”
Get full text

Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects by Rojas, Kristin, Spring, Laura M., O’Riordan, Liz, Weiss, Anna

“…Breast cancer patients are living longer than ever before and as such the population of breast cancer survivors continues to grow. Approximately 80% of breast…”
Get full text

Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities by Spring, Laura M., Nakajima, Erika, Hutchinson, Jennifer, Viscosi, Elene, Blouin, Gayle, Weekes, Colin, Rugo, Hope, Moy, Beverly, Bardia, Aditya

“…Patients with metastatic triple‐negative breast cancer have a poor prognosis. Sacituzumab govitecan (IMMU‐132) is an antibody‐drug conjugate that contains the…”
Get full text

Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception by Medford, Arielle J, Moy, Beverly, Spring, Laura M, Hurvitz, Sara A, Turner, Nicholas C, Bardia, Aditya

“…Breast cancer remains a leading cause of cancer-related death in women despite screening and therapeutic advances. Early detection allows for resection of…”
Get full text

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis by Spring, Laura M, Gupta, Arjun, Reynolds, Kerry L, Gadd, Michele A, Ellisen, Leif W, Isakoff, Steven J, Moy, Beverly, Bardia, Aditya

“…Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of…”
Get more information

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab by Filho, Otto Metzger, Viale, Giuseppe, Stein, Shayna, Trippa, Lorenzo, Yardley, Denise A, Mayer, Ingrid A, Abramson, Vandana G, Arteaga, Carlos L, Spring, Laura M, Waks, Adrienne G, Wrabel, Eileen, DeMeo, Michelle K, Bardia, Aditya, Dell'Orto, Patrizia, Russo, Leila, King, Tari A, Polyak, Kornelia, Michor, Franziska, Winer, Eric P, Krop, Ian E

“…Intratumor heterogeneity is postulated to cause therapeutic resistance. To prospectively assess the impact of HER2 ( ) heterogeneity on response to…”
Get more information

Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer by Wander, Seth A, Spring, Laura M, Bardia, Aditya

“…During the past decade, the use of combination targeted therapies for hormone receptor-positive, HER2-negative metastatic breast cancer has increased…”
Get full text